Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Incyte Holdings Corporation maintains a company patent portfolio with 1 pending office action currently active. This prosecution is situated in the Biotechnology & Pharmaceuticals technology area. The data shows that the company is working with a distinct examiner and 1 distinct art unit, reflecting a concentrated approach to its current filings.
The busiest examiner for this portfolio is LEE, WILLIAM Y, who is currently managing 1 busiest examiner pending action. This individual is the sole examiner responsible for the company's 1 pending office action. The concentration of work under a distinct examiner means that the prosecution outcomes are currently tied to a single reviewer's perspective.
The Biotechnology & Pharmaceuticals technology area encompasses the 1 distinct art unit where the company's work is being reviewed. With 1 pending office action, the portfolio's current footprint is precise. The busiest examiner pending action handled by LEE, WILLIAM Y represents the entirety of the company's active office action workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926010 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18926010 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS | LEE, WILLIAM Y | 1623 | DP | Non-Final OA | — | Pending | Oct 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIncyte Holdings Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
William Y Lee has the most, with 1 of Incyte Holdings Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
